Currently out of the existing stock ratings of Luca Issi, 115 are a HOLD (34.64%), 217 are a BUY (65.36%).

Luca Issi

Work Performance Price Targets & Ratings Chart

Analyst Luca Issi, currently employed at RBC, carries an average stock price target met ratio of 53.87% that have a potential upside of 46.37% achieved within 218 days.

Luca Issi’s has documented 634 price targets and ratings displayed on 35 stocks. The coverage is on Healthcare, Communication Services, Technology sectors.

Most recent stock forecast was given on ARGX, argenx NV ADR at 07-Jul-2026.

Wall Street Analyst Luca Issi

Analyst best performing recommendations are on NTLA (INTELLIA THERAPEUTICS).
The best stock recommendation documented was for NTLA (INTELLIA THERAPEUTICS) at 6/28/2021. The price target of $150 was fulfilled within 1 day with a profit of $16.57 (12.42%) receiving and performance score of 124.18.

Average potential price target upside

ALLO Allogene Therapeutics ALNY Alnylam Pharmaceuticals ARWR Arrowhead Pharmaceuticals BLUE Bluebird bio CRSP Crispr Therapeutics AG DRNA Dicerna Pharmaceuticals IONS Ionis Pharmaceuticals RGNX Regenxbio WVE Wave Life Sciences Ltd SGMO Sangamo Therapeutics ADVM Adverum Biotechnologies CRBU Caribou Biosciences EDIT Editas Medicine FIXX Homology Medicines NTLA Intellia Therapeutics GRPH Graphite Bio VERV Verve Therapeutics MRNA Moderna MGTX MeiraGTx Holdings PLC BEAM Beam Therapeutics  BMRN Biomarin Pharmaceutical QURE Uniqure NV FDMT 4D Molecular Therapeutics  APLS Apellis Pharmaceuticals DYN Dyne Therapeutics  RARE Ultragenyx RNA Avidity Biosciences  KRRO Frequency Therapeutics LXEO Lexeo Therapeutics, Common Stock ASND Ascendis Pharma AS ARGX argenx NV ADR FULC Fulcrum Therapeutics ADV Advantage Solutions AMGN Amgen BL Blackline

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 04-Apr-2023

$11

$8.87 (416.43%)

$12

2 months 28 days ago
(16-Apr-2026)

0/12 (0%)

$8.63 (364.14%)

Hold Since 21-Mar-2023

$3.85

$1.72 (80.75%)

$2.5

3 months ago
(14-Apr-2026)

2/3 (66.67%)

$1.13 (41.54%)

155

Buy Since 14-May-2025

$9

$6.87 (322.54%)

$9

3 months ago
(14-Apr-2026)

1/4 (25%)

$6.28 (230.88%)

19

Buy Since 05-Nov-2018

$8

$5.87 (275.59%)

4 months 1 days ago
(13-Mar-2026)

2/7 (28.57%)

$5.6 (233.33%)

3

Buy Since 04-Nov-2019

4 months 1 days ago
(13-Mar-2026)

1/2 (50%)

$28.66 (452.05%)

192

Show more analysts

Please expand the browser size to see the chart

Which stock is Luca Issi is most bullish on?

Potential upside of $146.24 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Luca Issi is most reserved on?

Potential downside of -$23.27 has been obtained for MRNA (MODERNA)

What Year was the first public recommendation made by Luca Issi?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?